Table 2.
Changes in Gonadotropin and Sex Steroid Levels After Implant Administration
| |
Baseline (T0) |
Follow-up T1 |
Z | p |
|---|---|---|---|---|
| SupprelinLA | Median (range) | Median (range) | ||
| LH (mIU/mL), n=43 | 0.62 (0.02–8.2) | 0.2 (0.02–1.29) | −4.15 | <0.001 |
| Follicle-stimulating hormone (mIU/mL), n=44 | 2 (0.66–9.2) | 0.63 (0.08–2.25) | −5.71 | <0.001 |
| Estradiol (pg/mL) (transmasculine), n=23 | 7 (2–48) | 2 (1–9) | −3.75 | <0.001 |
| Total testosterone (ng/dL) (transfeminine), n=22 | 19.5 (3–365) | 9 (3–28) | −3.58 | <0.001 |
| Vantas, n=20 | Baseline (T0) | Follow-up T1 | Z | p |
| LH (mIU/mL), n=20 | 1.26 (0.3–7.43) | 0.21 (0.08–0.92) | −3.68 | <0.001 |
| Follicle-stimulating hormone (mIU/mL), n=19 | 3.63 (0.9–7.58) | 0.5 (0.09–3.05) | −3.82 | <0.001 |
| Estradiol (pg/mL) (transmasculine), n=8 | 35.5 (18–90) | 3 (2–7) | −2.52 | <0.001 |
| Total testosterone (ng/dL) (transfeminine), n=10 | 57.5 (5–334) | 7 (3–13) | −2.83 | <0.001 |
Wilcoxon signed ranks tests.
LH, luteinizing hormone.